Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 9/20 | 0.61 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.46 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.46 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.46 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.46 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.46 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.46 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.46 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.46 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.46 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343211 | 0.85 | CACNA1B (0.59) | CACNA1BCTSLCTSKCTSSPSMB11 | |
| SCHEMBL7345242 | 0.85 | CACNA1B (0.57) | CACNA1BCTSLCTSKCTSSPSMB11 | |
| SCHEMBL7480901 | 0.85 | CACNA1B (0.58) | CACNA1BCTSLCTSKCTSSPSMB11 | |
| SCHEMBL7547062 | 0.85 | CACNA1B (0.57) | CACNA1BCTSLCTSKCTSSPSMB11 | |
| SCHEMBL7339830 | 0.84 | CACNA1B (0.68) | CACNA1BCTSLCTSSPSMB11PSMA7 | |
| SCHEMBL7428800 | 0.84 | CACNA1B (0.56) | CACNA1BCTSLCTSKCTSSPSMB11 | |
| SCHEMBL7343480 | 0.84 | IL1RN (0.62) | CACNA1BPSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL7343475 | 0.84 | IL1RN (0.62) | CACNA1BPSMB11PSMA7PSMB1PSMA1 | |
| SCHEMBL7341871 | 0.84 | CACNA1B (0.61) | CACNA1BCTSLCTSKCTSSPSMB11 | |
| SCHEMBL7341876 | 0.84 | CACNA1B (0.61) | CACNA1BCTSLCTSKCTSSPSMB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459430-B2 | Methods of using ziconotide to treat overactive bladder | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459430-B2 | Methods of using ziconotide to treat overactive bladder | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-6316440-B1 | TREATMENT OF STROKE, HEAD TRAUMA, CEREBRAL ISCHEMIA, PAIN AND EPILEPSY | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | CACNB2, RYR2, FABP2 | CACNA1B 7/4885CTSL 1032/4885CTSK 837/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | CACNA1B 10/4885CTSL 3645/4885CTSK 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.